Inflammatix-diagnostics

About Inflammatix

Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. Our expert bioinformatics and assay development teams are poised to build a host response-based diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection and other conditions. We are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.

Our Approach

Our approach to developing host response-based diagnostic tests has yielded remarkable results to date:

Every test should be built with a physician end-user in mind. Our team is physician-led, ensuring that development starts with the question of whether a test could be clinically actionable, and whether it fits into workflow. Our test for sepsis was built to answer a critical clinical gap: physicians usually guess about whether or not a patient needs antibiotics. Current pathogen-focused diagnostic methods fail to answer this question because they frequently miss infections that haven’t spread to the bloodstream. Thus, we focused on using the immune response to infections to answer to key clinical action items in the evaluation of an acutely ill patient: (1) does the patient need antibiotics, and (2) what level of care is required? These questions are best answered by ‘reading’ the immune response, rather than looking directly for a pathogen as a ‘needle in a haystack’.

Embrace “dirty data” in selecting and analyzing cohorts to study. Acute infections can be remarkably clinically diverse: kids and adults, inpatients and outpatients, in different settings around the world. We wanted to build a test that would work in every environment. We thus embrace this clinical heterogeneity by analyzing multiple cohorts that are diverse in their population, sample types, assays used and other factors. Our robust statistical pipeline allows us to find reproducible signal in the ‘noise’ of multiple datasets. Although this is a hard challenge, our discovery methods ensure that the diagnostics we find are generalizable to new populations.

Validate on multiple, independent and diverse cohorts. Trustworthy tests must demonstrate robust performance in independent, blinded multi-center studies.

Our Stellar Values

Leadership

Tim Sweeney, MD, PhD
Tim Sweeney, MD, PhDCo-Founder and CEO
Dr. Sweeney helped invent the core Inflammatix technology and is a licensed physician and data scientist.

Full Bio
Jonathan Romanowsky
Jonathan RomanowskyCo-Founder and Chief Business Officer
Mr. Romanowsky has over 15 years of novel, high-value molecular diagnostics commercialization experience.

Full Bio
Oliver Liesenfeld, MD
Oliver Liesenfeld, MDChief Medical Officer
Dr. Liesenfeld is an expert in the field of microbiology, infectious diseases and the host response.

Full Bio
Joao Fonseca, PhD
Joao Fonseca, PhDChief Technology Officer
Dr. Fonseca has over 15 years of experience in developing and launching breakthrough point of care diagnostic products

Full Bio
Ljubomir Buturovic, PhD
Ljubomir Buturovic, PhDVice President of Machine Learning
Dr. Buturovic leads his team in machine learning and artificial intelligence to validate clinical algorithms.

Full Bio
Yudong He, PhD, MBA
Yudong He, PhD, MBAVice President of Computational Biology
Dr. He is a scientific leader in Computational Biology with over 20 years of experience in the biotechnology and pharmaceutical industry.

Full Bio
Nina Menezes, PhD
Nina Menezes, PhDVice President of Marketing
Dr. Menezes leads the Marketing team to define and launch novel products using Inflammatix’s innovative technology platform.

Full Bio
Pamela Lambert, MS, PMP, CLS
Pamela Lambert, MS, PMP, CLSVice President of Program Management & Design Assurance
Ms. Lambert brings leadership expertise from over 30 years in scientific, management, and consulting positions in clinical laboratory, diagnostics, genomics, pharmaceutical, and medical device environments.

Full Bio
Paul Fleming, PhD
Paul Fleming, PhDVice President of Engineering
Dr. Fleming has over 10 years of experience exclusively developing life science and diagnostic instruments and consumables.

Full Bio
Howard Solovei
Howard SoloveiVice President Finance and Business Operations
Mr. Solovei has 20+ years of deep finance and accounting experience in high growth medical device and fintech companies.

Full Bio
Purvesh Khatri, PhD
Purvesh Khatri, PhDCo-Founder and Scientific Advisor
Dr. Khatri is an Associate Professor at the Stanford Institute for Immunity, Transplantation and Infection.

Full Bio

Board of Directors

Tim Sweeney, MD, PhD
Tim Sweeney, MD, PhDCo-Founder and CEO
Dr. Sweeney is a licensed physician and data scientist with over 10 years of experience researching sepsis.

Full Bio
Steve Tablak
Steve TablakFormer Chairman and CEO, GeneWeave
Mr. Tablak joined GeneWeave with a great idea for a transformative IVD and helped to build a great company.
Michael Rubin, MD, PhD
Michael Rubin, MD, PhDFounder and CEO at Northpond Ventures
Northpond Ventures is a global, science driven venture capital firm dedicated to the mission of “Building a Better Tomorrow.”

Full Bio
Ken Bahk, PhD
Ken Bahk, PhDCEO of Lakewood Holdings
Lakewood Holdings provides for- and non-profit support of revolutionary entrepreneurs to advance healthcare.

Full Bio

Advisors

Jesús Bermejo-Martin, MD, PhD
Jesús Bermejo-Martin, MD, PhDPrincipal Investigator, BioSepsis
Jesus F Bermejo-Martin, MD, PhD, trained in Medicine at the University of Valladolid, Spain.

Full Bio
Hector Wong, MD
Hector Wong, MDProfessor of Pediatrics
Dr. Wong is a Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center.

Full Bio
Nathan A Ledeboer
Nathan A LedeboerProfessor and Vice Chair of Pathology
Dr. Ledeboer is a Professor at the Medical College of Wisconsin.

Full Bio
Jim Ducharme
Jim DucharmeClinical Professor of Medicine
Dr Ducharme is a Clinical Professor of Medicine at McMaster University.

Full Bio

Investors

Inflammatix investors include the following groups:

Partner with Us!

Inflammatix is establishing partnerships with diagnostic instrument, companion therapeutic and commercial distribution companies across the globe. Contact us at info@inflammatix.com to explore collaboration opportunities.

Our current partners include Genentech, DRIVe, BARDA and DARPA

Awards

Inflammatix is recognized for our accomplishments and promise

2020 MedTech Innovator Top 50 Medtech Startups

2019 FierceMedTech Fierce 15 Company

2019 AACC Disruptive Technology and Audience Choice Awards

2017 ISF Best Clinical Abstract Award

Stay in touch with Twitter updates: Find out the latest news.

Connect with Twitter